Vinod Balachandran, MD
Surgery · New York, NYNPI 1306085006
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.9%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Genentech, Inc. at 39.3% of the total. Reporting peaked in 2022 at $28,490 and has fallen 71.6% since, to $8,101 in 2025. Among surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $1780.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$23K
- AbbVie$13K
- Merck$13K
- F. Hoffmann-la Roche AG$5K
- Pfizer$3K
- Genentech USA, Inc.$935
- plus $412 from 3 others
Across 52 payments — averaging $57,507 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3M
What the payments were for
- Consulting fees$34,64259%
- Grants$18,75032%
- Travel & lodging$4,3107%
- Food & beverage$1,0652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $23,120 |
| AbbVie | 14 | $13,270 |
| Merck | 7 | $13,060 |
| F. Hoffmann-la Roche AG | 4 | $5,370 |
| Pfizer | 1 | $2,600 |
| Genentech USA, Inc. | 2 | $935 |
| AstraZeneca | 1 | $184 |
| Eli Lilly | 1 | $148 |
| Hologic Inc | 1 | $80 |
How this compares
$58,767 in reported general payments places this provider in the 95th percentile of 1,596 surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgery in New York
- Cheguevara AfanehNew York$1.4M
- Flavio Malcher Martins de OliveiraNew York$695K
- Yuri NovitskyNew York$548K
- Rasa ZarnegarNew York$478K
- Tanuja DamaniNew York$459K
- Rache SimmonsNew York$371K
- Marina KurianNew York$328K
- Megan JenkinsNew York$290K
- Brian JacobNew York$225K
- Robin BlackstoneNew York$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.